Trial Profile
Study of using second-line chemotherapy plus Apatinib in local recurrence or metastatic breast cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 13 Oct 2017 New trial record